Based on this Agreement, Viatris has completed marketing and promotion of the product as of 15 December 2023, but will continue to provide transition support until Sandoz will gradually assume responsibilities for the product starting 15 February 2024.

Biocon Biologics has acquired the global biosimilars portfolio of Viatris including Adalimumab. Fujifilm Kyowa Kirin Biologics Co., the developer of the drug, has concluded an exclusive global marketing license agreement with Biocon Biologics affiliate.

Adalimumab BS for subcutaneous injection [FKB] is a biosimilar of Humira® (generic name: adalimumab (genetical recombination)) and is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Sandoz is committed to further strengthening its product pipeline to drive sustainable business growth. The transfer of the distribution rights of this product is part of this strategy, and its addition to the product portfolio will strengthen Sandoz's immunology and biosimilar portfolio.